BioAlliance Pharma presents results on its new biotherapy plasmid AMEP™ for metastatic melanoma at the American Association for Cancer Research (AACR) 100th Annual Meeting in Denver, April 18 to 22, 2009

BioAlliance Pharma SA (Euronext Paris – BIO), a specialty
pharmaceutical company focused on the treatment of opportunistic infections in cancer and
HIV, has presented results on its new biotherapy, plasmid AMEP™, for metastatic melanoma
treatment at the at the American Association for Cancer Research (AACR) 100th Annual
Meeting, in Denver, April 18 to 22, 2009.
Worldwide melanoma incidence is about 140 000 per year with a high frequency especially in
Australia, North America and Europe. When treated at early stage, the prognosis of local
melanoma is excellent and associated with a prolonged survival. Nevertheless, the five-year
survival rate of advanced or metastatic cancers is low, between 5 and 25% according to the
stage and localisation of the disease. No treatments or treatment strategies are
demonstrated to be consistently effective in these advanced melanoma patients.
Recommendations from all medical and scientific cancer and dermatology societies are thus
to evaluate new treatments.
BioAlliance Pharma develops a new biotherapy, plasmid AMEP™, which displays antiangiogenic
and anti-metastatic properties. AMEP™ binds avb3 and a5b1 integrins which are
receptors overexpressed by tumoral melanocytes and also activated endothelial cells
involved in new blood vessel formation.
Results presented during the AACR annual meeting describe these anti-angiogenic and antitumoral
properties of the plasmid AMEP™ biotherapy in in vitro and in vivo models. In an in
vivo experimental model of invasive melanoma, tumor treatment by plasmid AMEP™
biotherapy, applied through either intratumoral or intramuscular route, induced a strong
tumor growth inhibition (>95% and >50% respectively). Moreover, preliminary acute
toxicology studies show that plasmid AMEP™ biotherapy is safe and well-tolerated.
Preclinical toxicology and biodistribution regulatory studies are in progress and will allow the
submission of the regulatory file for a phase I clinical trial planned in 2009 in metastatic
melanoma patients.
About the American Association of Cancer Research (AACR)
The mission of the AACR is to prevent and cure cancer through research, education, communication,
and collaboration. Through its programs and services, the AACR fosters research in cancer and
related biomedical science, accelerates the dissemination of new research findings among scientists
and others dedicated to the conquest of cancer, promotes science education and training and
advances the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the

090421AACRAmep_ EN